Ovarian Cancer Cell Lines

NOV-002 acts as lead compounds chemoprotection and an immunomodulator. It is marketed in Russia under the trade name PharmaBAM Glutoxim ®, and has been administered to more than 5,000 patients, demonstrating clinical efficacy and excellent safety. The U.S. Phase 1 / 2 clinical trial in November-002 for lung cancer in non-small cell (NSCLC) has been completed, with positive results. During an end of Phase 2 meeting rooms, the FDA agreed that the promotion in November-002 in a pivotal Phase 3 trial evaluating in advanced NSCLC in combination with a first-line chemotherapy is justified. In May 2006, finalized a Special Protocol Assessment Novelos (SPA) with FDA for a single pivotal trial, received Fast Track designation in August 2006, this Phase 3 began in November 2006. November-002 is also in Phase 2 development for ovarian cancer resistant to chemotherapy and breast cancer in early stage and is also being developed for acute radiation injury.

No. .. I did not know that!

yes